SCHEMBL4037478

SCHEMBL4037478

O=C1NC(=S)NC(=O)C1=Cc1ccc(C=Cc2ccccc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 6/20 0.76
SIRT1 Q96EB6 3/20 0.76
SIRT5 Q9NXA8 3/20 0.76
SIRT3 Q9NTG7 2/20 0.76
METAP1 P53582 2/20 0.66
ALDH1A1 P00352 2/20 0.55
RAB9A P51151 1/20 0.55
MAPK1 P28482 2/20 0.55
KDM4E B2RXH2 1/20 0.55
MEN1 O00255 1/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
NTSR1 P30989 1/20 0.55
KMT2A Q03164 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
EP300 Q09472 1/20 0.53
PPARG P37231 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13848496 1.00 SIRT2 (0.76) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL1520357 0.93 SIRT2 (0.80) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL10134156 0.82 SIRT2 (0.69) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL4041531 0.82 SIRT2 (0.69) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL4044276 0.79 METAP1 (1.00) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL13848519 0.79 METAP1 (1.00) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL13848499 0.79 METAP1 (0.69) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL15421462 0.79 METAP1 (0.73) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL13587000 0.79 SIRT2 (0.69) SIRT2SIRT1SIRT5SIRT3METAP1
SCHEMBL30020331 0.79 METAP1 (1.00) SIRT2SIRT1SIRT5SIRT3METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305026-B1 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS NOVUSPHARMA SPA (IT) 2009-05-13 EP disclosed
US-20080113993-A1 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS VIA ARIOSTO, 23 (IT) 2008-05-15 US disclosed
US-20030229108-A1 Barbituric acid analogs as therapeutic agents NOVUSPHARMA S.P.A. (IT) 2003-12-11 US disclosed
EP-1305026-A2 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS Novuspharma S.p.A. (IT) 2003-05-02 EP disclosed
WO-2001093841-A2 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS NOVUSPHARMA S.P.A. (IT) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229108-A1 Barbituric acid analogs as therapeutic agents HIF1AN, HIF1A, VHL SIRT2 656/4885SIRT1 166/4885SIRT5 1201/4885
US-20080113993-A1 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS HIF1A, HIF1AN, PDGFA SIRT2 904/4885SIRT1 139/4885SIRT5 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.